AP NEWS

CENTOGENE Announces Updates to CentoMD®, World’s Largest Genetic Mutation Database of Rare Diseases

November 6, 2018

ROSTOCK, Germany--(BUSINESS WIRE)--Nov 6, 2018--CENTOGENE today announced updates to CentoMD®, the world’s largest genetic mutation database of rare diseases. The newest release further bridges the critical gap between genetic variants and clinical interpretation, by combining precise clinical genetic and biomarker information. Newly generated knowledge and data are now based off of disease causing variants confirmed by biomarker data. This unique combination standardizes and expedites the medical interpretation of these variants, coming from more than 300,000 individuals located in more than 115 countries.

CentoMD ® provides information about the genotype-phenotype correlation based on clinical cases analyzed at CENTOGENE. The database is evidence-based and includes:

More than 62,000 classified and curated variants More than 7.3 million variants, 58 percent of which are unpublished More than 3,500 associated phenotypes More than 13,300 human phenotype ontology (HPO) terms and approximately 330,000 individuals-HPO associations

“The biggest challenge in treating hereditary rare diseases is achieving an early diagnosis in order to identify the issue before it progresses too far and to provide counselling and start treatment as soon as possible. Unfortunately, the reality is that it can take more than five years on average to diagnose a rare hereditary disease. This is far too long,” said Dr. Arndt Rolfs, founder and CEO of CENTOGENE. “With our latest iteration of CentoMD ®, we are providing clinicians and geneticists with the most complete information about genetic variants for making crucial diagnoses at the earliest possible moment.”

About CENTOGENE CENTOGENE unlocks the power of genetic insights to improve the quality of life of patients with rare genetic diseases. We achieve this through knowledge created by our worldwide diagnostic testing services incorporating global diversity, the world’s leading proprietary human genetic interpretation database- CentoMD ® and by providing solutions for pharmaceutical companies developing life-changing therapies.

As one of the largest genetic testing companies worldwide, CENTOGENE is dedicated to translating the science of genetic information into solutions- bringing hope to patients with rare diseases and their families. www.centogene.com; www.centoMD.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20181106005144/en/

CONTACT: CENTOGENE:

Doreen Niemann, +49 381 80113510

doreen.niemann@centogene.com

or

CENTOGENE Media Contact:

MacDougall Biomedical Communications

Lauren Arnold, +1 781-235-3060

larnold@macbiocom.com

KEYWORD: EUROPE GERMANY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: CENTOGENE

Copyright Business Wire 2018.

PUB: 11/06/2018 08:00 AM/DISC: 11/06/2018 08:01 AM

http://www.businesswire.com/news/home/20181106005144/en

AP RADIO
Update hourly